RDi has confirmed it will continue its long‑standing role supporting the NHS Bowel Cancer Screening Programme, following NHS England’s appointment of GXO Logistics as the managed service provider for the national provision of bowel cancer home testing kits.
Having been involved in the programme since 2008, RDi plays a critical role in enabling population‑level screening through the design, assembly and delivery of high‑quality diagnostic kitting and data‑enabled processes. This work has helped millions of people across England take part in bowel cancer screening safely and conveniently from their own homes.
Under the new partnership model, GXO will manage the supply and distribution of Faecal Immunochemical Test (FIT) kits, working alongside specialist partners including MAST, the world’s largest distributor of FITs, and RDi, the UK’s leading end‑to‑end diagnostic kitting partner. Together, the partnership brings together deep expertise across logistics, diagnostics and manufacturing to support one of the NHS’s most important national prevention programmes.
The NHS Bowel Cancer Screening Programme is a core pillar of the NHS prevention strategy supporting earlier diagnosis by making screening more accessible and improving participation across eligible populations. The programme is widely recognised as a strong example of how specialist partners can work collaboratively at scale to strengthen national screening pathways and address health inequalities.
Eric Finton James, Senior Director, Healthcare, GXO UK & Ireland, said:
“This agreement aligns with the NHS 10 Year Health Plan to move care from hospitals to community settings, with a continued focus on prevention. FIT home testing kits help identify those at risk of cancer who require further tests, and their provision is an essential component of NHS England’s screening pathway. Our expertise will ensure that those who need a test receive it, and that laboratories conducting the tests have the equipment they need to successfully screen patients.”
Iain McElarney, Innovation Manager at Mast, said:
“Mast has been developing FIT solutions in Bowel Cancer Screening across Europe since 2005 and are particularly proud to continue our work with the English Bowel Cancer Screening Programme, providing excellent participant experience and driving innovation in laboratory testing.”
David Cahill, CEO of RDi, said:
“RDi has been proud to support the NHS Bowel Cancer Screening Programme since its early days, helping to enable self‑sampling at national scale and supporting efforts to increase participation and address inequalities. We are absolutely delighted to continue working as a key partner as the programme enters its next phase.”
As the UK’s leading end‑to‑end diagnostic kitting partner, RDi designs, manufactures, assembles and fulfils clinically compliant diagnostic and self‑sampling solutions, supported by robust digital processes that enable traceability, quality assurance and scalability. This capability continues to play a vital role in supporting NHS England’s ambition to move care closer to home and strengthen early detection through prevention‑focused pathways.
